Login to Your Account



Search

Search results

Pharma: Clinic Roundup

• Sanofi SA , of Paris, reported full results from the EDITION II study of investigational insulin U300, showing that 23 percent fewer patients experienced night-time low blood sugar compared with Lantus (insulin glargine [rDNA origin] injection). ...

BioWorld Today - Staff - 2013-12-04 01:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Janssen Pharmaceutica NV , of Beerse, Belgium, part of Johnson & Johnson, reported results of the PALMFlexS study. Data showed flexible maintenance dosing with Xeplion (paliperidone palmitate) was associated with a clinically relevant treatme ...

BioWorld Today - Staff - 2013-12-03 01:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Pfizer Inc. , of New York, said it entered an agreement with Glaxosmithkline plc , of London, to explore the anticancer efficacy and safety of GSK’s trametinib (GSK1120212) combined with Pfizer’s palbociclib (PD-0332991) in a Phase I/II study ...

BioWorld Today - Staff - 2013-11-22 01:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• CSL Ltd. , of King of Prussia, Pa., presented data at the American Heart Association meeting in Dallas showing that CSL112 demonstrated favorable safety and tolerability when administered to patients with stable atherothrombotic disease and showed ...

BioWorld Today - Staff - 2013-11-21 01:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Boehringer Ingelheim GmbH , of Ingelheim, Germany, reported clinical results from a study of 145 healthy male volunteers showing that its fully humanized antibody fragment (Fab) rapidly reversed the anticoagulation effect of dabigatran, with onset ...

BioWorld Today - Staff - 2013-11-20 01:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Astrazeneca plc , of London, said it will conduct two new trials designed to build scientific understanding of Brilinta (ticagrelor) tablets in additional high-risk patient populations. One trial involves 9,600 patients who have experienced an acut ...

BioWorld Today - Staff - 2013-11-15 01:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Takeda Pharmaceutical Co. Ltd. , of Osaka, Japan, reported top-line results from the GEMINI I Phase III study of vedolizumab in 895 patients with moderately to severely active ulcerative colitis who have failed at least one conventional thera ...

BioWorld Today - Staff - 2012-02-22 01:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• The ALS Therapy Development Institute (ALS TDI) said it plans to launch a Phase II trial of TDI 132 (fingolimod/Gilenya) in amyotrophic lateral sclerosis. Gilenya, a first-in-class sphingosine-1-phosphate (S1P) receptor modulator marketed by ...

BioWorld Today - Staff - 2012-02-15 01:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Baxter International Inc. , of Deerfield, Ill., said it completed enrollment in its Phase III trial of BAX 855, an extended half-life recombinant Factor VIII treatment for hemophilia A. (BioWorld-Today-2013-11-14) ...

BioWorld Today - Staff - 2013-11-14 01:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Eli Lilly and Co. , of Indianapolis, reported data from a Phase III study showing that both Cialis (tadalafil) and tamsulosin significantly improved scores on the International Prostate Symptom Score, compared to placebo, in men with signs an ...

BioWorld Today - Staff - 2012-02-08 01:00 - 0 comments - 0 attachments